Abediterol - AstraZeneca

Drug Profile

Abediterol - AstraZeneca

Alternative Names: AZD-0548; LAS 100977

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios Almirall
  • Developer AstraZeneca
  • Class Antiasthmatics; Bronchodilators; Quinolines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 18 May 2018 Phase-II clinical trials in Asthma (Inhalation) before May 2018
  • 18 May 2018 Adverse events, efficacy and pharmacokinetics data from a phase IIa trial in Asthma presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 18 May 2018 Pharmacokinetics data from a phase I trial in Asthma presented at the 114th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top